Pretreatment Claudin-18.2 Expression Predicts Poorer Survival Outcomes in Locally Advanced Gastric Cancer Treated with Perioperative Chemotherapy

<b>Background/Objectives</b>: Claudin-18.2 (CLDN18.2) has recently emerged as a therapeutic target in gastric cancer; however, its prognostic relevance in the neoadjuvant setting remains insufficiently defined. We evaluated the clinical significance of CLDN18.2 and fibroblast growth factor receptor...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Gürkan Gül, Özlem Kutlu, Asuman Argon, Halil Taşkaynatan, Özlem Özdemir
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2026-04-01
سلاسل:	Diagnostics
الموضوعات:	gastric cancer CLDN18.2 neoadjuvant chemotherapy immunohistochemistry prognostic biomarker relapse-free survival
الوصول للمادة أونلاين:	https://www.mdpi.com/2075-4418/16/9/1277
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!